2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Korman N, Warren R, Bagel J, Armstrong A, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli L, Kisa R, Banerjee S, Blauvelt A. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. Journal Of Dermatological Treatment 2024, 35: 2371045. PMID: 38945549, DOI: 10.1080/09546634.2024.2371045.Peer-Reviewed Original ResearchConceptsMaintenance of responseModerate to severe plaque psoriasisOnset of actionSevere plaque psoriasisPlaque psoriasisApremilast-treated patientsEfficacy measuresOral placeboClinical responseCoprimary endpointsDeucravacitinibPsoriasis trialsWeek 8PlaceboPASIPatientsWeek 1WeeksEfficacyPsoriasisSPGABaselineSignificant improvementTrialsApremilast
2023
42828 Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials
Papp K, Lebwohl M, Hong H, Kircik L, Pariser D, Strober B, Krueger G, Krupa D, Burnett P, Berk D, Higham R. 42828 Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials. Journal Of The American Academy Of Dermatology 2023, 89: ab156. DOI: 10.1016/j.jaad.2023.07.625.Peer-Reviewed Original Research43778 Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Strober B, Puig L, Blauvelt A, Thaçi D, Elewski B, Wang M, Vanvoorden V, Deherder D, Staelens F, Wiegratz S, Paul C. 43778 Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial. Journal Of The American Academy Of Dermatology 2023, 89: ab21. DOI: 10.1016/j.jaad.2023.07.092.Peer-Reviewed Original Research43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial
Strober B, Kivitz A, Östör A, Padilla B, Yue C, Photowala H, Merola J. 43944 Improvements in Manifestations of Active Psoriatic Arthritis With Risankizumab Treatment After Intolerance or Inadequate Response to Prior Biologic Therapy: Subgroup Analyses From the KEEPsAKE 2 Trial. Journal Of The American Academy Of Dermatology 2023, 89: ab179. DOI: 10.1016/j.jaad.2023.07.717.Peer-Reviewed Original Research41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials
Armstrong A, Blauvelt A, Papp K, Green L, Feely M, Malatestinic W, See K, McKean-Matthews M, Strober B. 41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials. Journal Of The American Academy Of Dermatology 2023, 89: ab12. DOI: 10.1016/j.jaad.2023.07.056.Peer-Reviewed Original ResearchTapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial
Strober B, Zeichner J, Desai S, Cameron M, Cather J, Bruno M, Rubenstein D, Tallman A, Brown P. Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial. SKIN The Journal Of Cutaneous Medicine 2023, 7: s125. DOI: 10.25251/skin.7.supp.125.Peer-Reviewed Original Research
2022
Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Blauvelt A, Stein Gold L, Gooderham M, Strober B, Pinter A, Carrascosa J, Gisondi P, Bleier J, Madden C, Deherder D, Gomez N, Warren R. Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials. SKIN The Journal Of Cutaneous Medicine 2022, 6: s67. DOI: 10.25251/skin.6.supp.67.Peer-Reviewed Original ResearchBimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension
Thaçi D, Vender R, De Rie M, Conrad C, Soung J, Strober B, Wang M, Cross N, Deherder D, Gomez N, Gottlieb A. Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension. SKIN The Journal Of Cutaneous Medicine 2022, 6: s68. DOI: 10.25251/skin.6.supp.68.Peer-Reviewed Original ResearchBimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials
Pinter A, Strober B, Rosmarin D, Gisondi P, Vanvoorden V, Peterson L, Madden C, De Cuyper D, Warren R. Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials. SKIN The Journal Of Cutaneous Medicine 2022, 6: s73. DOI: 10.25251/skin.6.supp.73.Peer-Reviewed Original ResearchBimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials
Lebwohl M, Armstrong A, Merola J, Gottlieb A, Davis L, Gomez B, Wiegratz S, Cross N, Strober B. Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials. SKIN The Journal Of Cutaneous Medicine 2022, 6: s64. DOI: 10.25251/skin.6.supp.64.Peer-Reviewed Original Research34321 Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
Strober B, Paul C, Blauvelt A, Thaçi D, Elewski B, White K, Vanvoorden V, Deherder D, Staelens F, Eyerich K. 34321 Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial. Journal Of The American Academy Of Dermatology 2022, 87: ab146. DOI: 10.1016/j.jaad.2022.06.614.Peer-Reviewed Original Research35205 Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials
Augustin M, Strober B, Armstrong A, Beaumont J, Pham T, Hudgens S, Zhuo J, Becker B, Banerjee S, Kisa R, Papp K. 35205 Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials. Journal Of The American Academy Of Dermatology 2022, 87: ab156. DOI: 10.1016/j.jaad.2022.06.656.Peer-Reviewed Original ResearchTapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Blauvelt A, Kircik L, Brown P, Tallman A, Lebwohl M. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN The Journal Of Cutaneous Medicine 2022, 6: s5. DOI: 10.25251/skin.6.supp.5.Peer-Reviewed Original Research
2021
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Blauvelt A, Brown P, Kircik L, Tallman A, Lebwohl M. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN The Journal Of Cutaneous Medicine 2021, 5: s35. DOI: 10.25251/skin.5.supp.35.Peer-Reviewed Original ResearchBimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial
Strober B, Asahina A, Mrowietz U, Lebwohl M, Foley P, Langley R, Barker J, Cioffi C, Cross N, Wang M, Paul C. Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. SKIN The Journal Of Cutaneous Medicine 2021, 5: s52. DOI: 10.25251/skin.5.supp.52.Peer-Reviewed Original Research25843 Tapinarof cream 1% once daily for plaque psoriasis: Patient-reported outcomes from two pivotal phase 3 trials
Bissonnette R, Strober B, Lebwohl M, Bagel J, Del Rosso J, Merola J, Bhatia N, Yamauchi P, Brown P, Rubenstein D, Tallman A. 25843 Tapinarof cream 1% once daily for plaque psoriasis: Patient-reported outcomes from two pivotal phase 3 trials. Journal Of The American Academy Of Dermatology 2021, 85: ab71. DOI: 10.1016/j.jaad.2021.06.310.Peer-Reviewed Original Research27374 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial
Strober B, Pinter A, Warren R, Blauvelt A, Sebastian M, De Cuyper D, Vanvoorden V, Wang M, Madden C, Gooderham M. 27374 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial. Journal Of The American Academy Of Dermatology 2021, 85: ab138. DOI: 10.1016/j.jaad.2021.06.569.Peer-Reviewed Original Research27505 Bimekizumab short-term and longer-term anxiety, depression, and suicidal ideation/behavior in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials
Strober B, Papp K, Blauvelt A, Lebwohl M, Wu J, Deherder D, Madden C, Wixted K, Wang M, Augustin M. 27505 Bimekizumab short-term and longer-term anxiety, depression, and suicidal ideation/behavior in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials. Journal Of The American Academy Of Dermatology 2021, 85: ab149. DOI: 10.1016/j.jaad.2021.06.611.Peer-Reviewed Original ResearchA Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm
Strober B, Pariser D, Deren-Lewis A, Dickerson T, Lebwohl M, Menter A. A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm. Dermatology And Therapy 2021, 11: 1851-1860. PMID: 34275121, PMCID: PMC8484423, DOI: 10.1007/s13555-021-00573-1.Peer-Reviewed Original ResearchPatient outcomesCommunity dermatologistsPsoriasis treatment responseNon-responding patientsFirst-line therapySuboptimal patient outcomesBiologic switchingBiologic agentsPsoriasis managementTherapy utilizationBiologic classesTherapeutic responseTreatment paradigmTreatment responseClinical utilityBiologic drugsPatientsDrug selectionMethodsA surveyPrior authorizationDermatologistsFirst choiceTrialsBiologic responsePrecision medicineBimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials
Reich K, Blauvelt A, Lebwohl M, Papp K, Rich P, Strober B, De Cuyper D, Madden C, Peterson L, Vanvoorden V, Warren R. Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials. SKIN The Journal Of Cutaneous Medicine 2021, 5: s21. DOI: 10.25251/skin.5.supp.21.Peer-Reviewed Original Research